Research digest · Four-peptide blend
KLOW peptide is a four-arm research blend, read here one study at a time.
KPV, GHK-Cu, BPC-157 and TB-500, composed into a single vial — with what each component's literature actually measured surfaced first, and the untested combination left honestly blank.
The short version
KLOW peptide is not one drug. It is four research peptides mixed together in a single vial — KPV, GHK-Cu, BPC-157 and TB-500 — sold for laboratory use only. The most common version holds 80 mg total: 50 mg of GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV. The four are dissolved together, but they stay four separate molecules; the blend is not a new chemical.
The idea behind it is tissue repair. Each peptide works on a different step of how the body mends itself — calming inflammation, rebuilding the scaffolding under skin, growing new blood vessels, and helping cells migrate to close a wound. Those single-peptide effects are real and cited below. What is not proven is the blend: no controlled study has ever tested all four together. Everything said about "KLOW" as a combination is reasoned from the parts. What people report — including the downsides — is on the effects page.
What is KLOW peptide?
KLOW peptide is a research-only co-formulation (several distinct compounds dissolved in one vial at fixed ratios) of four chemically separate peptides: KPV, GHK-Cu, BPC-157 and TB-500. It is supplied for laboratory and research use only, and none of the four is FDA-approved for human use.
A central, honest fact frames everything here: the four-peptide KLOW blend itself has never been tested in any controlled study — not against a single peptide, not against any subset, not against placebo. The research that exists is single-component research. So this digest reads each constituent against its own studies and marks the join between them as the blank it is.
What is KLOW peptide?
KLOW peptide is a single vial holding four separate peptides at fixed mass ratios. It is not a single molecule and not an approved drug; it is a research chemical (a substance supplied for laboratory work, not labeled for human or veterinary use). The most widely listed composition is GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg [1][3][4].
Inside the KLOW blend: four peptides, one vial
The KLOW blend pairs four peptides whose mechanisms sit at different, largely non-overlapping points of one tissue-repair network. KPV is the anti-inflammatory arm: the tripeptide Lys-Pro-Val, the tail end (residues 11-13) of the hormone alpha-MSH. It is pulled into gut and immune cells by a transporter called PepT1 and quiets NF-kB, a master switch for inflammatory genes [3]. GHK-Cu is the mass-dominant arm and the matrix builder: a copper-carrying tripeptide (Gly-His-Lys bound to a copper ion) that shifts a large share of a cell's gene activity toward rebuilding the extracellular matrix — the scaffolding around cells — and supplies copper for the enzymes that cross-link collagen [4][5].
BPC-157 is the angiogenesis (new-blood-vessel) arm: a 15-amino-acid peptide derived from a protein found in stomach juice, studied heavily in rodent tendon and gut repair [2]. TB-500 is the cell-migration arm: a short fragment (Ac-LKKTET-Q) of the larger natural protein thymosin beta-4, which binds the building blocks of actin to help cells crawl and close wounds [6]. Most of the strongest data here are for the full-length protein, not the short TB-500 fragment — a distinction this site keeps throughout.
The KLOW peptide blend at a glance
The KLOW peptide blend is four arms of one repair cascade composed into one vial: inflammation suppression (KPV), matrix remodeling (GHK-Cu), blood-vessel growth (BPC-157) and cell migration (TB-500). The components are not additive into a single "KLOW dose," and the combination has no controlled evidence of its own.
What is in the 80 mg KLOW peptide vial?
The canonical research vial is 80 mg total, split GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg — so GHK-Cu is roughly 62.5% of the vial by mass [4]. The four are co-dissolved at these fixed ratios; they do not fuse into one substance. There is no FDA-approved or pharmacopeial KLOW product, and no single CAS number or molecular weight describes the mixture — each peptide keeps its own identity (KPV 342.44 Da, GHK-Cu 402.92 Da, BPC-157 1419.53 Da, TB-500 889.02 Da).
The blue tint sometimes noted in a reconstituted vial traces to the copper(II) in GHK-Cu; copper complexes are characteristically blue, and GHK-Cu is the dominant component [4].
What the KLOW stack is built to do
The KLOW stack is assembled around a single thesis: that four complementary steps of repair — calming the cytokine storm, rebuilding matrix, restoring blood supply, and mobilizing cells to close the gap — work better composed than alone. Each step has its own evidence. KPV reduced the severity of chemically-induced colitis in mice and cut inflammatory signaling in human gut-cell cultures at nanomolar concentrations [3]. GHK-Cu modulates roughly 31% of assayed human genes at a 50%-or-greater change threshold, with strong effects on matrix, antioxidant and DNA-repair programs [5].
BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures [2]. And thymosin beta-4 — the parent of the TB-500 fragment — increased re-epithelialization (the regrowth of skin's surface layer) by 42% at four days and up to 61% at seven days in a rat wound model [1]. The thesis is reasonable. It is also, for the blend itself, untested: no study has put the four together. The full wound-healing research is set out study by study.
What does the KLOW peptide do?
What does the KLOW peptide do?
KLOW pairs four peptides whose individual mechanisms occupy non-overlapping nodes of one tissue-repair network: inflammation suppression (KPV), matrix remodeling (GHK-Cu), angiogenesis (BPC-157) and cell migration with wound closure (TB-500/thymosin beta-4) [1][2][3][4]. The blend is framed around tissue repair, not metabolism — none of its components is a weight-loss or blood-sugar agent.
What is KLOW peptide used for?
In research, KLOW is framed around tissue repair: the four arms target cytokine suppression, matrix synthesis, new-vessel growth and cell migration as complementary steps of one cascade [3][4][2][1]. All blend-level use claims are extrapolated from single-component studies; the combination has never been tested in a controlled setting. For the reported, plain-English picture — and its limits — see the KLOW peptide benefits page and the reported side effects.